The outcome of patients with high‐risk MDS achieving stable disease after treatment with 5‐azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group
- 7 September 2018
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 36 (4), 693-700
- https://doi.org/10.1002/hon.2551
Abstract
The demethylating factor 5‐Azacytidine (5‐AZA) improves survival in intermediate‐2 and high risk MDS patients [according to the International Prognostic Score System (IPSS)] responding to treatment. However, the outcome of patients achieving stable disease (SD) is unclear. This retrospective study of the Hellenic MDS Study Group included 353 intermediate‐2 or high IPSS‐risk patients treated with 5‐AZA. 44 out of 86 (51.6%) patients achieving SD and continuing treatment with 5‐AZA showed a lower risk of transformation of MDS to AML and increased overall survival (OS), compared to SD patients who discontinued the treatment (estimated median AML‐free survival = 38 months, 95% CI = 10.7–65.3 vs. 15 months, 95% CI = 10.4–19.6, pvs. 11 months, 95% CI = 5.8–16.2, pvs. 31 months, 95% CI = 23.6–38.4, p=0.45; estimated median OS 20 months, 95% CI = 5.5 – 34.5 vs. 25 months, 95% CI = 21.3–28.7, p=0.50). In conclusion, MDS patients achieving SD in the first six months of treatment with AZA as best response should continue receiving AZA as they may benefit from prolonged treatment.Keywords
This publication has 10 references indexed in Scilit:
- Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsLeukemia Research, 2016
- Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the ‘real life’ setting: A single center observational studyHematology, 2015
- Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agentsLeukemia & Lymphoma, 2015
- How we treat higher-risk myelodysplastic syndromesBlood, 2014
- Myelodysplastic syndromes: 2014 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2014
- A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialHaematologica, 2013
- Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic ChallengesAsco Educational Book, 2013
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.Blood, 2007
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006